Suchergebnisse - "Yi, Zongbi"

PubPharm (11)

1

Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients

enthalten in: Cancer medicine | 2022

von Liu, B. | Yi, Z. | Guan, Y. | +10

2

The molecular tumor burden index as a response evaluation criterion in breast cancer

enthalten in: Signal transduction and targeted therapy | 2021

von Yi, Z. | Ma, F. | Rong, G. | +10

3

Mutational characteristics determined using circulating tumor DNA analysis in triple-negative breast cancer patients with distant metastasis

enthalten in: Cancer communications (London, England) | 2020

von Rong, G. | Yi, Z. | Ma, F. | +4

4

Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers

enthalten in: Breast (Edinburgh, Scotland) | 2020

von Yi, Z. | Liu, B. | Sun, X. | +10

5

Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer

enthalten in: International journal of cancer | 2020

von Ma, F. | Guan, Y. | Yi, Z. | +16

ErratumIn: Int J Cancer. 2020 Jun 15;146(12):E8. - PMID 32320496

6

Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer

enthalten in: Breast (Edinburgh, Scotland) | 2020

von Guan, X. | Liu, B. | Niu, Y. | +9

7

Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients : A Phase I Clinical Trial

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2019

von Li, Q. | Guan, X. | Chen, S. | +16

8

Everolimus in hormone receptor-positive metastatic breast cancer : PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study

enthalten in: BMC cancer | 2019

von Yi, Z. | Ma, F. | Liu, B. | +5

9

Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2017

von Ma, F. | Li, Q. | Chen, S. | +13

CommentIn: J Clin Oncol. 2017 Sep 20;35(27):3089-3091. - PMID 28783451

10

Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition : a proof-of-principle study on the heterogeneity of circulating tumor cells

enthalten in: Oncotarget | 2016

von Guan, X. | Ma, F. | Liu, S. | +7